Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symptom-driven ICS/LABA Therapy for Asthma Patients Non-adherent to Daily Maintenance Inhalers
NCT05111262Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2021
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of budesonide and formoterol in asthma (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Adherence to inhaler strategy delineated using an electronic inhaler sensor at 24 weeks. Started Dec 2021; status: active, not recruiting.
02
Drugs
budesonideformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05111262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111262.